Knowledge Hub
Knowledge Hub
Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.
Page 1 of 1
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Read
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Read
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.
ReadNeuroendocrine Cancer New Zealand mourns the passing of Associate Professor Dr Malcolm Legget, a tireless advocate for NET patients.
Read
After six years as CEO, Siobhan Conroy stepped down from the Unicorn Foundation NZ board, leaving behind a transformed landscape for NET patients.
ReadPatients on octreotide were switched to a new funded brand in late 2021. NECNZ asked nurses and patients to help monitor any side effects.
Read
Minister of Health Hon Andrew Little officially launched the new PRRT service for New Zealand neuroendocrine cancer patients in July 2021.
Read